William Blair downgraded CymaBay (CBAY) to Market Perform from Outperform after Gilead (GILD) agreed to acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3B.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CBAY:
- M & A News: Gilead (NASDAQ:GILD) Snaps Up CymaBay (NASDAQ:CBAY) for $32.50 Per Share
- CymaBay Therapeutics’ Strategic Merger with Gilead Sciences
- CymaBay Therapeutics to Participate in Upcoming Investment Conferences
- CymaBay price target raised to $26 from $22 at Oppenheimer
- CymaBay Therapeutics Boosts Director Equity, Announces Officer Changes